Medpace Holdings, Inc. (NASDAQ:MEDP) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have been given an average rating of “Hold” by the thirteen research firms that are presently covering the firm, MarketBeat reports. Ten analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $584.1818.

A number of analysts recently issued reports on the stock. TD Cowen raised their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Mizuho boosted their target price on Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Truist Financial upped their price target on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. BMO Capital Markets increased their price objective on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research report on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $535.00 target price on shares of Medpace in a research note on Thursday, July 23rd.

Medpace Trading Down 0.6%

Shares of MEDP stock opened at $578.50 on Monday. Medpace has a 12-month low of $373.00 and a 12-month high of $677.90. The stock has a 50 day simple moving average of $536.23 and a 200-day simple moving average of $492.35. The company has a market cap of $16.15 billion, a price-to-earnings ratio of 33.91, a price-to-earnings-growth ratio of 2.60 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the previous year, the company earned $3.10 EPS. The company’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities analysts forecast that Medpace will post 17.54 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In other news, VP Susan E. Burwig sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total value of $4,500,000.00. Following the transaction, the vice president directly owned 62,984 shares in the company, valued at approximately $37,790,400. This trade represents a 10.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Cornelius P. Mccarthy III sold 1,140 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $605.37, for a total value of $690,121.80. Following the transaction, the director owned 12,275 shares of the company’s stock, valued at $7,430,916.75. This represents a 8.50% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 67,195 shares of company stock valued at $37,989,998. Company insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Medpace

Several hedge funds have recently made changes to their positions in MEDP. Johnson Financial Group Inc. purchased a new position in Medpace in the 2nd quarter worth about $27,000. Steigerwald Gordon & Koch Inc. acquired a new position in Medpace in the 4th quarter valued at approximately $30,000. Elyxium Wealth LLC acquired a new position in shares of Medpace in the fourth quarter worth $30,000. Jones Financial Companies Lllp acquired a new position in Medpace in the 2nd quarter worth about $30,000. Finally, Allied Private Wealth LLC acquired a new position in Medpace in the second quarter worth approximately $31,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.